German generics major Stada Arzneimittel (SAZ: Xetra) has posted results for full-year 2018, showing strong growth momentum for the company.
Group sales increased 1% to 2.33 billion euros ($2.64 billion). Sales of Stada Vietnam JV were no longer included in the 2018 figures. Allowing for this, group sales rose 5%.
Key growth drivers of generics sales were Belgium, Italy and Germany and the consumer health had strong momentum in the UK and Germany.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze